Von Zerssen Depression Scale Research Articles

Psychopathology Assessment Methods Revisited: On Translational Cross-Validation of Clinical Self-Evaluation Scale and fMRI.

We present in this article a study design that combines clinical self-assessment scale, simultaneously administered with fMRI data acquisition. We have used a standard block-design with two different conditions. Each active block consisted of four text statements (items), alternating diagnostically specific (DS) blocks comprising items from von Zerssen depression scale and diagnostically neutral (DN) blocks with items from a questionnaire about general interests. All items were rated on four degree Likert scale, and patients provided responses with corresponding four buttons during the fMRI session. Our results demonstrated that in healthy controls, contrasting the two types of stimuli yielded no residual activations, e.g., the DS did not produce significantly different activations compared to the DN stimuli. Furthermore, the correlation analyses did not find a relationship between brain activations and the total score of the DS statements in this group. However, contrasting the DS stimuli to the DN stimuli in the patients produced significant residual activations in several brain regions: right pre- and postcentral gyrus (including right supramarginal gyrus), left middle frontal gyrus, triangular part of the left inferior frontal gyrus and middle temporal gyrus. The left precuneus demonstrated correlations with the patients’ DS score. In the between-group comparisons, we found residual activations in the right pre- and postcentral gyrus, right supplementary motor area, medial segment of the right precentral gyrus, right superior parietal lobule, left middle frontal gyrus, left superior frontal gyrus, left occipital pole. Our results confirm the possibility of translational cross-validation of a clinical psychological test (von Zerssen’s depression scale) and fMRI. At this stage, however, we can only confirm the sensitivity of the method (its ability to distinguish healthy controls from depressed patients), but we cannot conclude anything about its specificity (distinction from different psychopathology conditions).

Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder

Silexan, a novel lavender oil preparation for oral use, has been authorized in Germany for the treatment of states of restlessness during anxious mood. An open-label, exploratory trial was performed to assess the potential of the medicinal product in the treatment of restlessness caused by anxiety as related to several disorders. Outcome measures included the Symptom Checklist-90-Revised (SCL-90-R), von Zerssen's Depression Scale (D-S), the 36-item Short Form Health Survey Questionnaire (SF-36), and a sleep diary.50 male and female patients with neurasthenia (ICD-10 F48.0), post-traumatic stress disorder (PSD; F43.1), or somatization disorder (F45.0, F45.1) were included to receive 1×80mg/day Silexan over 6 weeks; 47 could be analyzed for efficacy as full analysis set. At baseline, patients suffered from restlessness (96%), depressed mood (98%), sleep disturbances (92%), or anxiety (72%). Of those, resp. 62%, resp. 57%, resp.51%, resp. 62% showed improvements during treatment (p<0.001). For all patients, mean D-S score decreased by 32.7% and SCL-90-R Global Severity Index by 36.4% as compared to baseline, (p<0.001), while the SF-36 Mental Health Score increased by 48.2% (p<0.001). Waking-up frequency (p=0.002), Waking-up duration (p<0.001) and morning tiredness (p=0.005) were reduced, while efficiency of sleep (p=0.018) and mood (p=0.03) improved. Patients suffering from neurasthenia or PSD showed comparable improvements with most outcomes.The results in this trial justify to further investigate Silexan in disorders with accompanying restlessness caused by sub-threshold anxiety. Adverse reactions, predominantly gastrointestinal complaints, were judged as mild or moderate.

Die Kontrollüberzeugung ist ein Prädiktor für CPAP-Compliance bei obstruktivem Schlafapnoesyndrom

Approximately 25 % of all patients suffering from obstructive sleep apnea syndrome (OSAS) discontinue CPAP-therapy in long-term follow-up. This study was conducted to investigate if there are any predictors signaling low compliance prior to initiation of CPAP-therapy. We used an open label longitudinal cohort study at an University hospital in-patient Sleep laboratory setting. In 85 consecutive patients with a diagnosis of OSAS confirmed by polysomnography a CPAP-therapy was initiated. Prior to CPAP-titration the subjects were interviewed using standardized, validated questionnaires (Nottingham Health Profile, von Zerssen's Depression Scale, State Trait Anxiety Inventory, IPC-Scale). On follow up (mean 16 +/- 8 month) 66 patients were still using CPAP regularly, 19 individuals had discontinued the therapy. Data of both groups were compared. There were no significant differences in polysomnographic parameters before CPAP except apnea-hypopnea-index (users: 30.72 +/- 20.68, rejecters: 18.43 +/- 10.43) and mean oxygen saturation (users: 91.65 +/- 3.32, rejecters 93.63 +/- 1.86). Depression and anxiety levels were normal in both groups. The subjects who discontinued CPAP had a significantly less external control belief. Internal control belief was normal in all patients. It is suggested that individuals who discontinued CPAP could not be convinced of the necessity of CPAP by physicians or nurses due to their reduced external control belief. Identifying patients with diminished external control belief prior to prescription of a device might be useful. In selected subgroups, different methods of motivation to maintain long-term acceptance for CPAP-therapy seems to be necessary.

Gender Differences in Coping with Tension-Type Headaches

Objective: To study gender differences of coping with illness strategies in tension-type headaches. Method: We enrolled 89 subjects (50 women, 39 men) suffering from episodic (n = 37) and chronic (n = 52) tension-type headaches (TTH). Patients were required to answer a Freiburg Questionnaire of Coping with Illness (FQCI), a Von Zerssen Depression Scale (D-S), quality-of-life questionnaires, and a headache home diary (over 4 weeks). In addition, pressure pain thresholds (temporal muscles) and Total Tenderness Scores were obtained. Results: While pain intensity, frequency and quality-of-life parameters were basically the same for female and male episodic TTH sufferers, women scored significantly higher on the F3 subscale (distracting and encouraging) of the FQCI and tended to score higher on the F1 subscale (depressive). Among chronic TTH patients, women reported the pain to be more intense (VAS), were more depressed (D-S), and scored lower on several quality-of-life scores. Female chronic TTH sufferers scored significantly lower on the F2 subscale (active coping) and tended to score higher on F5 (denying). Conclusions: We conclude that pessimistic coping with illness strategies are more frequent in female episodic and chronic TTH sufferers. We would like to recommend special psychologic intervention in particular to female chronic TTH sufferers which would offer counseling in developing active coping skills.

Coping strategies in episodic and chronic tension-type headache.

To study the importance of coping with illness strategies in tension-type headache (TTH). The pathophysiology of TTH is complex, and coping with illness strategies might contribute to the transformation to a chronic form. We examined 89 subjects (mean age, 45.6 +/- 14.8 years; range, 18 to 72 years) with episodic (n = 37) and chronic (n = 52) TTH. Patients were required to fill in a Freiburg Questionnaire of Coping with Illness (FQCI), a von Zerssen Depression Scale, quality-of-life questionnaires, and a headache home diary (over 4 weeks). In addition, pressure pain thresholds (temporal muscles) and total tenderness scores were obtained. Patients with chronic TTH exhibited poorer quality-of-life measures, slightly more depressive symptoms, and significantly stronger avoidance behavior and endurance strategies on FQCI scales F4 and F5 (P< .05). There was no difference between episodic and chronic TTH with respect to measures of muscle tenderness or pain thresholds. We conclude that disadvantageous coping with illness strategies might contribute to a transformation to chronic TTH.

Coping with refractory epilepsy

We investigated the coping behaviour and its correlation with demographic and illness-related data, depression, locus of control and psychosocial adaptation in 40 patients with intractable epilepsy with primarily or secondarily generalized tonic–clonic seizures. Three standardized self-reporting questionnaires were applied, which are the Freiburg Questionnaire of Coping with Illness (FKV), the von Zerssen Depression Scale (D-S), and the IPC-questionnaire measuring generalized locus of control beliefs; the Social Interview Schedule (SIS), a semi-structured interview, was used to measure the psychosocial adaptation. Active, problem-focused and compliance strategies were predominantly used and regarded as most helpful. Hence, the epileptic patients use similar coping patterns reported in patients with other non life-threatening chronic diseases. The level of depression was moderate and in the range of other chronic somatic diseases. The use of coping patterns, which are regarded as maladaptive, was correlated with distinct depression, a small degree of internal locus of control beliefs and poor psychosocial adaption. These results indicate the possibility to improve psychosocial adjustment by supporting effective strategies.

Befuraline, its Safety and Efficacy in Depressed Inpatients

Befuraline, a new antidepressant drug, was studied in twenty-nine inpatients with unipolar endogenous depression. The evaluation of patients' condition was made on four different study periods by two assessors using the HDRS, the Beck depression inventory and von Zerssen depression scale. Befuraline, given in oral doses of between 100 and 300 mg/day improved the HDRS total score and the cognitive disturbances to a significant extent (p less than 0.01) after the first week of the treatment. Eleven patients withdrew from the study most of them as a result of intolerance to the stimulatory properties of the drug, however, the response was considered satisfactory in 12 of the 29 patients (41%) mostly in the "retarded depressed" class. As Befuraline proved to be well tolerated, it was continued on an outpatient basis in 11 patients, confirming the absence of clinically important untoward effects.